Unexpectedly high variability in determining tumour extent in prostatic biopsies: implications for active surveillance
Authors:
Open Access
- 28 November 2024
- journal article
- research article
- Published by Wiley in Histopathology
- Vol. 86 (4) , 627-639
Abstract
Aims: Tumour content in prostatic biopsies is an important indicator of prostate cancer volume and patient prognosis. Consequently, guidelines typically recommend reporting it as a percentage or linear length (mm). This study aimed to determine the current practices for reporting tumour content in prostatic biopsies and evaluated the consistency among pathologists in diagnosing 10 standard biopsy cases of prostate cancer to assess interobserver variability.Methods and results: A web‐based survey gathered data on demographics, experience and attitudes regarding the reporting of prostate cancer and its extent in biopsies. Virtual microscopy allowed analysis of 10 biopsy cases, each consisting of a single slide of prostate cancer. Self‐reports from 304 participants recruited via the International Society of Urological Pathology and the German Society of Pathology were analysed. Most participants (43.4%) reported tumour extent as percentage of the biopsy core, 37.6% reported percentages and mm and 18.3% reported mm exclusively. The methods used to determine percentages showed an unexpected spread of choices, leading to considerable variability in results. Additionally, 40.8% of participants took part in the practical segment of the survey. The reported measures of tumour extent confirmed a notable interobserver variability, which was significantly higher for reported percentages.Conclusion: A high rate of interobserver variability in reporting tumour content in prostatic biopsies was found. This matter is especially critical for patients who are candidates for active surveillance. Reporting absolute measures of tumour content has the advantage of lower variability in comparison to percentages.Keywords
This publication has 25 references indexed in Scilit:
- The impact of pre‐biopsy MRI and additional testing on prostate cancer screening outcomes: A rapid reviewBJUI Compass, 2024
- Quantification of overdiagnosis in randomised trials of cancer screening: an overview and re-analysis of systematic reviewsCancer Epidemiology, 2023
- Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy StrategyEuropean Urology, 2022
- Interobserver reproducibility of perineural invasion of prostatic adenocarcinoma in needle biopsiesVirchows Archiv, 2021
- Standardization of reporting discontinuous tumor involvement in prostatic needle biopsy: a systematic reviewVirchows Archiv, 2021
- EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)European Urology, 2019
- Dataset for the reporting of prostate carcinoma in core needle biopsy and transurethral resection and enucleation specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR)Pathology, 2019
- Variation in reporting of cancer extent and benign histology in prostate biopsies among European pathologistsVirchows Archiv, 2014
- Tissue shrinkage after fixation with formalin injection of prostatectomy specimensVirchows Archiv, 2006
- The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomyCancer, 2003